Financial PerformanceThe company reported total revenue of $28.8M, compared to the consensus estimate of $11.6M, and a net income of $0.04 per share, compared to the consensus estimated a net loss of $0.12 per share.
Management And LeadershipThe appointment of new C-suite management and board of directors, including experienced leaders from CTI BioPharma, is expected to strengthen X4 Pharmaceuticals' position.
Strategic PartnershipsX4 entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of Xolremdi in Europe, Australia, and New Zealand, with potential E.U. approval in 1H26.